Year All20242023202220212020201920182017201620152014 May 10, 2022 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results May 02, 2022 Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome Apr 01, 2022 Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering Mar 31, 2022 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results Mar 29, 2022 Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering Mar 28, 2022 Soleno Therapeutics Announces Proposed Underwritten Public Offering Mar 09, 2022 Running for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome Feb 08, 2022 Soleno Therapeutics to Participate in the BIO CEO & Investor Conference Jan 28, 2022 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 24, 2022 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
May 10, 2022 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 02, 2022 Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome
Apr 01, 2022 Soleno Therapeutics Announces Closing of Approximately $15 Million Underwritten Public Offering
Mar 31, 2022 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results
Mar 29, 2022 Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
Mar 09, 2022 Running for Research – Prader-Willi Syndrome to Fund Multi-Center Study of DCCR in Early Phase Prader-Willi Syndrome
Jan 24, 2022 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome